203 related articles for article (PubMed ID: 34648118)
1. Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
Zheng F; Du F; Wang W; Wang Y; Li M; Zhao J; Wang X; Yue J; Wang J; Yang Z; Cai R; Ma F; Fan Y; Li Q; Zhang P; Xu B; Yuan P
Breast Cancer Res Treat; 2022 Jan; 191(1):97-105. PubMed ID: 34648118
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
Du F; Wang W; Wang Y; Li M; Zhu A; Wang J; Cai R; Ma F; Fan Y; Li Q; Zhang P; Todorovic V; Yuan P; Xu B
Breast Cancer Res Treat; 2020 Jul; 182(1):67-77. PubMed ID: 32394350
[TBL] [Abstract][Full Text] [Related]
3. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD; Ye FG; He M; Fan L; Ma D; Mo M; Wu J; Liu GY; Di GH; Zeng XH; He PQ; Wu KJ; Hou YF; Wang J; Wang C; Zhuang ZG; Song CG; Lin XY; Toss A; Ricci F; Shen ZZ; Shao ZM
JAMA Oncol; 2020 Sep; 6(9):1390-1396. PubMed ID: 32789480
[TBL] [Abstract][Full Text] [Related]
4. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
6. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Zhang P; Yin Y; Mo H; Zhang B; Wang X; Li Q; Yuan P; Wang J; Zheng S; Cai R; Ma F; Fan Y; Xu B
Oncotarget; 2016 Sep; 7(37):60647-60656. PubMed ID: 27447966
[TBL] [Abstract][Full Text] [Related]
7. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L; Wu ZY; Li J; Lin Y; Liu Z; Cao Y; Zhang G; Gao HF; Yang M; Yang CQ; Zhu T; Cheng MY; Ji F; Li J; Wang K
Int J Cancer; 2022 Feb; 150(4):654-662. PubMed ID: 34591977
[TBL] [Abstract][Full Text] [Related]
10. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Lahdenperä O; Kosonen S; Villman K; Nyandoto P; Nilsson G; Poikonen-Saksela P; Kataja V; Junnila J; Bono P; Lindman H
JAMA Oncol; 2017 Jun; 3(6):793-800. PubMed ID: 28253390
[TBL] [Abstract][Full Text] [Related]
12. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Untch M; von Minckwitz G; Konecny GE; Conrad U; Fett W; Kurzeder C; Lück HJ; Stickeler E; Urbaczyk H; Liedtke B; Beckmann MW; Salat C; Harbeck N; Müller V; Schmidt M; Hasmüller S; Lenhard M; Nekljudova V; Lebeau A; Loibl S; Fasching PA;
Ann Oncol; 2011 Sep; 22(9):1999-2006. PubMed ID: 21382868
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Iwase M; Ando M; Aogi K; Aruga T; Inoue K; Shimomura A; Tokunaga E; Masuda N; Yamauchi H; Yamashita T; Iwata H
Breast Cancer Res Treat; 2020 Apr; 180(3):687-694. PubMed ID: 32140811
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Geyer CE; Sikov WM; Huober J; Rugo HS; Wolmark N; O'Shaughnessy J; Maag D; Untch M; Golshan M; Lorenzo JP; Metzger O; Dunbar M; Symmans WF; Rastogi P; Sohn JH; Young R; Wright GS; Harkness C; McIntyre K; Yardley D; Loibl S
Ann Oncol; 2022 Apr; 33(4):384-394. PubMed ID: 35093516
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense paclitaxel plus carboplatin
Li Q; Wang J; Mu Y; Zhang T; Han Y; Wang J; Li Q; Luo Y; Ma F; Fan Y; Zhang P; Xu B
Chin J Cancer Res; 2020 Aug; 32(4):485-496. PubMed ID: 32963461
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
18. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Yin Y; Zhang P; Xu BH; Zhang BL; Li Q; Yuan P; Cai RG; Wang JY; Wang X; Xu XZ
J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):262-265. PubMed ID: 23592141
[TBL] [Abstract][Full Text] [Related]
19. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
[TBL] [Abstract][Full Text] [Related]
20. Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.
Yuan P; Kang Y; Ma F; Fan Y; Wang J; Wang X; Yue J; Luo Y; Zhang P; Li Q; Xu B
JAMA Netw Open; 2023 Feb; 6(2):e230122. PubMed ID: 36826820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
